Anteris Technologies is developing DurAVR, a differentiated biomimetic TAVR device with encouraging early clinical data in over 130 patients. AVR’s PARADIGM pivotal trial is the central catalyst. This ...
Cardiovascular disease remains a leading global health burden, yet many preclinical systems still struggle to predict how candidate drugs will perform in the human heart.
This article examines how bioprinting improves cancer models, overcoming traditional limits and advancing current therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results